The American Association of Psychiatric Pharmacists (AAPP) is a professional association representing nearly 3,000 psychiatric pharmacists. AAPP’s membership consists of specialized pharmacists, many being Board Certified Psychiatric Pharmacists (BCPP), who treat patients living with psychiatric disorders, including substance use disorders (SUD).
Psychiatric pharmacists are on the frontlines providing direct patient care, optimizing medication outcomes, and supporting fellow health care providers in furnishing primary care and mental health services. Unfortunately, insufficient reimbursement continues to stand in the way of many practices and institutions including a psychiatric pharmacist on the care team. To expand the use of these qualified providers and help ease the strain on the health care workforce, federal payment policies must be changed to allow psychiatric pharmacists to directly bill for their comprehensive medication management (CMM) services.
Patients with psychiatric disorders, including SUD, are confronted with a health care system that lacks mental health and SUD providers and is unable to meet their care and treatment needs. Additionally, research shows that the COVID-19 pandemic greatly exacerbated existing mental health issues leading to substantial increases in anxiety, depression, and SUD spanning from the young to the aged. Americans deserve high-quality, evidence-based, measurement-driven, comprehensive care that psychiatric pharmacists can provide if integrated as members of interprofessional teams.
To increase access to psychiatric pharmacist patient care services, AAPP’s federal policy priorities for 2024 are as follows:
AAPP will play an active role in legislative and regulatory advocacy to:
Increase understanding and awareness by policymakers, health care professional organizations, and patient advocacy organizations on the role of psychiatric pharmacists and the value they add to the health care team and their impact on patient outcomes.
Increase access to comprehensive medication management (CMM) services for psychiatric disorders, including SUD by:
Advocating for Medicare coverage of CMM services and recognition of psychiatric pharmacists as providers.
Ensuring sufficient payment for psychiatric pharmacists’ services.
Expanding the mental health and substance use disorder treatment workforce through use of psychiatric pharmacists.
Increasing adoption of innovative care and payment models that integrate services for mental health and SUD into primary care.
AAPP will actively work with key partners to advance legislative and regulatory policies to:
Maintain access to psychiatric and substance use services provided through telehealth, including removing initial in-person visit requirements.
Advocate for policies that increase access and remove barriers to mental health and substance use treatment medications such as long-acting injectable antipsychotics, naloxone, and medication for the treatment of alcohol and opioid use disorders including:
Removing barriers to access to medications for opioid use disorder (MOUD) such as:
Expanding methadone treatment beyond the Opioid Treatment Program (OTP) setting, including take-home doses for stable patients and pick-up doses at pharmacies.
Implementing low barrier access to tele-prescribed controlled substances while maintaining appropriate safeguards.
Enforcing of the Mental Health Parity and Addiction Equity Act of 2008.
Simplifying FDA Risk Evaluation and Mitigation Strategies (REMS) that significantly impact patient care and access to medication.
Addressing structural and policy barriers that result in shortages of medication.
Minimizing the use of and standardizing the process for utilization management, including prior authorization and step therapy by health plans.
Maintaining the six-protected classes of covered medications in Medicare Part D.
Increase CMS funding for psychiatric pharmacy residency training including pharmacy residency (PGY1) and psychiatric pharmacy residency (PGY2) training.
Maintain the 340B Drug Pricing Program (340B) as essential in providing low-income patients access to medically necessary medications as well as psychiatric pharmacists’ services and residency training.
Prevent suicide by ensuring timely access to mental health care, including access to psychiatric pharmacists.
Reduce stigma and dispel mental health myths and misperceptions perpetuated around individuals living with mental health disorders, including substance use disorders.
By continuing to use the site, you agree to this collection.
We are undergoing major upgrades right now, and we appreciate your patience.
If you need help, please use the support chat or email email@example.com.